IDEXX LABORATORIES INC /DE Impairment of Intangible Assets, Finite-lived
IDEXX LABORATORIES INC /DE (IDXX) reported Impairment of Intangible Assets, Finite-lived of $2.20 million for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2018-02-16
- IDEXX LABORATORIES INC /DE impairment of intangible assets, finite-lived for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
- IDEXX LABORATORIES INC /DE impairment of intangible assets, finite-lived for the quarter ending 2016-06-30 was $0.00.
- IDEXX LABORATORIES INC /DE impairment of intangible assets, finite-lived for the quarter ending 2016-03-31 was $2.20M.
- IDEXX LABORATORIES INC /DE impairment of intangible assets, finite-lived for the quarter ending 2015-12-31 was $0.00.
- IDEXX LABORATORIES INC /DE impairment of intangible assets, finite-lived for fiscal 2015 was $8.21M.
- IDEXX LABORATORIES INC /DE impairment of intangible assets, finite-lived for fiscal 2009 was $1.51M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 3 month as first filed | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|---|
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $0.00 derived: sum of 2 quarters · filed 2017-10-31 | $2.20M 10-Q · filed 2016-11-01 | $2.20M derived: sum of 4 quarters · filed 2018-02-16 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-10-31 | $2.20M 10-Q · filed 2017-10-31 | $2.20M derived: sum of 3 quarters · filed 2018-02-16 | $10.41M derived: sum of 4 quarters · filed 2018-02-16 | |
| 2016-03-31 | $2.20M 10-Q · filed 2017-04-28 | $1.10M 10-Q · filed 2016-04-29 | $2.20M derived: sum of 2 quarters · filed 2018-02-16 | $10.41M derived: sum of 3 quarters · filed 2018-02-16 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $8.21M derived: sum of 2 quarters · filed 2018-02-16 | $8.21M 10-K · filed 2018-02-16 | ||
| 2015-09-30 | $8.21M 10-Q · filed 2015-10-28 | $8.21M 10-Q · filed 2015-10-28 | |||
| 2009-12-31 | $1.51M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |